— Know what they know.
Not Investment Advice

CSL.AX

CSL Limited
1W: +2.2% 1M: -1.5% 3M: -22.4% YTD: -17.7% 1Y: -45.2% 3Y: -50.2% 5Y: -44.1%
A$144.50 ($100.31)
+3.51 (+2.49%)
 
ASX · Healthcare · Biotechnology · A$68.4B · Alpha Radar Sell · Power 36
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market CapA$68.4B ($47.5B)
52W Range133.35-275.79
Volume1,005,234
Avg Volume1,222,246
Beta0.21
DividendA$4.27
Analyst Ratings
No analyst coverage
Company Info
CEOGordon Naylor DipCompSc
Employees32,698
SectorHealthcare
IndustryBiotechnology
IPO Date1994-06-01
Websitecsl.com.au
45 Poplar Road
Melbourne, VIC 3052
AU
61 3 9389 1911
About CSL Limited

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms